|To Get Update On Mobile Text STOCKS to 67076|
|The #1 Newsletter for Highly Profitable Penny Stock Alerts|
|our New Trade Alert Is QBIO|
Today, we would like to bring to your attention a new trade opportunity.
This little known company could be positioned for incredible growth.
New Trade Alert: Q BioMed Inc. (QBIO)
Small companies often create the most impactful innovations.
In fact, larger companies need help from small companies to grow.
This is the case in many industries, but specifically in biotech.
According to Pharma Intelligence, “big pharma has long been licensing and acquiring R&D assets from outside.”
Additionally, “smaller biotechs, with new technologies and creative, focused approaches” “have proven better at discovering new drugs than large pharma.”
One of these small overlooked companies, which could have a tremendously positive impact in the biotech industry, is our new trade alert – QBIO.
QBIO is a “biotech acceleration and commercial stage company” “focused on licensing and acquiring undervalued biomedical assets in the healthcare sector.”
QBIO provides “strategic resources, developmental support and expansion capital” so that products can reach patients in need.
The company has a growing pipeline of “drug candidates with significant value in large markets of underserved patients.”
QBIO “believes its assets in oncology, vascular disease, and rare orphan diseases address unmet medical needs and large markets.”
One of the large markets that requires significant attention is the unfortunate development of the opiod epidemic in the US.
According to the National Institute on Drug Abuse, “every day, more than 130 people in the United States die after overdosing on opioids” while “roughly 21 to 29 percent of patients prescribed opioids for chronic pain misuse them.”
“The Centers for Disease Control and Prevention estimates that the total “economic burden” of prescription opioid misuse alone in the United States is $78.5 billion a year”.
This problem has created a new demand for non-opioid solutions for chronic pain.
As physicians curtail their use of opioids, QBIO could become more relevant than ever to investors.
The company shocked many when it recently announced: “Q BioMed Inc Announces Acquisition of Cancer Pain Drug Metastron™ from GE Healthcare”
According to the company’s March 19th press release:
“The Company’s FDA approved, non-opioid drug Metastron, which relieves cancer bone pain, is expected to begin generating revenues in 2019.”
“Metastron is also approved for sale in 21 other countries.”
“In addition to treating pain, Metastron has shown evidence of treating the cancer itself and extending survival.”
“Q BioMed plans to conduct Phase IV trials to support label extension and cancer survival benefit using Metastron.”
But that’s not all…
In addition, QBIO has an opportunity to address the glaucoma market, which according to Bright Focus “is a leading cause of irreversible blindness in the United States and the world” with it estimated to affect “almost 80 million by 2020.”
In March, the company announced:
But why now? Why should you care?
Most recently, in April, the company announced what could be a significant milestone:
“In a Major Breakthrough, Q BioMed Discovers First Biomarkers for Pediatric Nonverbal Autism Subgroup”
Here are the highlights from this press release:
“Q BioMed CEO, Denis Corin highlighted, “This is a major breakthrough for these children and their families. To date, very little attention and research has been focused on these nonverbal autistic children. In partnership with the clinical and advocacy community, Q BioMed is leading the effort to better stratify this group, while also pursuing a treatment.”
According to the company:
“There are approximately 18,000-20,000 new cases of pediatric nonverbal autism in the U.S. each year and a similar amount in Europe. The majority of the children are diagnosed by the age of seven and fall within the autism spectrum. Individually, the economic costs for toddlers that become non- or minimally verbal is $10 million dollars on average per child over a lifetime.”
“Collectively, an estimated $200 billion is spent yearly on individuals who are nonverbal in the U.S. Not all individuals who are nonverbal will benefit from QBM-001. However, with validated biomarkers, testing from trained specialists and genetic testing, children who fall in this targeted population can be identified, and will have a higher likelihood of responding to an approved treatment.”
This is a potentially massive win for the company.
QBIO has a history of experiencing significant upside.
At the start of 2019 QBIO rallied from as low as 0.98 to a high of more than 2.40, experiencing gains of more than 144%.
Since this massive rally QBIO has consolidated below its 50 and 200 day moving averages (DMA) and could once again be positioned for a breakout higher.
QBIO has a 50 DMA of 1.87 and a 200 DMA of 2.04, 14% and 25% above today’s close, presenting what could be an opportunity for increased upside.
QBIO has a relative strength index (RSI) of 41, suggesting the opportunity for gains.
QBIO has experienced a remarkable 2019 thus far, announcing multiple accomplishments.
As the company continues to execute its vision, it could present investors with significant growth potential.
Make sure to do your own due diligence.
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term trade opportunities.
Trading Rules [Please Review Before Taking Any Action]:
Don’t forget to try our Free Easy-to-Use SMS service for real-time alerts and winning tips. Simply send the message STOCKS to the number 67076.
1,989 total views, 1 views today